In September revenues increased by 30%, substantial increase in all major markets


JSC Olainfarm preliminary consolidated results for September 2019 indicate that revenues increased by 30% compared to the same month last year and reached 12.4 million euro. At the same time consolidated results for the first nine months of 2019 show that revenues reached 98.8 million euro which is an increase by 11%, compared to the nine-month period of 2018. Extraordinary rapid increase in sales was in Ukraine, Kazakhstan and Uzbekistan markets. Products of Olainfarm Group during this period were sold in 54 markets worldwide.

Consolidated sales in September show revenue increase in all of the main markets. In Russia sales grew by 21%, in Latvia by 9%, in Belarus by 67%, in Ukraine by 137%, in Kazakhstan by 823%, in Moldova by 46%, in Uzbekistan by 542%, in Lithuania by 63% and in Poland by 45%. Brazil was among the largest markets where products were sold in amount of 151 thousand EUR.

In the nine months of 2019, the main sales markets of Olainfarm Group continued to contribute 78% of the total revenue – Latvia’s  and Russia’s share was 28%, Belarus (12% share) and Ukraine (8% share). Other major sales markets included Kazakhstan, Uzbekistan, the Netherlands, Germany, Tajikistan and Italy. The most rapid sales growth during this nine-month period was achieved in the Netherlands, where sales grew by 188% compared to the last year, and in Uzbekistan where sales grew by 50%. Sales in Russia improved by 10%, in Latvia by 12%, in Belarus by 9%, in Kazakhstan by 13%, in Tajikistan by 18% but in Italy by 40%. Amongst the largest sales outlets a decline was marked in Ukraine (-1%).

JSC "Olainfarm" continues to show strong sales results by increasing sales in all major markets in September. We are also expanding our cooperation with new foreign partners, such as those from Egypt and Brazil. Deliveries of the anti-tuberculosis drug PASS sodium will continue in October, according to the contract. With the aim of strengthening both production and export capacity, we are expanding our manufacturing facility, acquiring new equipment, and strengthening the company’s marketing team by attracting a professional with long-standing experience, “says Lauris Macijevskis, Chairman of the Management Board of JSC Olainfarm.

September 2019, consolidated sales   Sales, thous. EUR Share in total sales Changes to September 2018
Russia 4 841 39% 21%
Latvia 3 212 26% 9%
Belarus 1 168 9% 67%
Ukraine 808 7% 137%
Kazakhstan 391 3% 823%
Moldova 207 2% 46%
Uzbekistan 182 1% 542%
Lithuania 165 1% 63%
Poland 163 1% 45%
Brazil 151 1% N/A
Other 1 115 9% 0%
Total 12 404 100% 30%

9 months 2019, consolidated sales Sales, thous. EUR Share in total sales Changes to 9 months 2018
Russia 28 973 29% 10%
Latvia 28 375 29% 12%
Belarus 11 906 12% 9%
Ukraine 8 121 8% -1%
Kazakhstan 2 555 3% 13%
Uzbekistan 2 427 2% 50%
Netherlands 1 802 2% 188%
Germany 1 498 2% 4%
Tajikistan 1 267 1% 18%
Italy 1 102 1% 40%
Other 10 769 11% 4%
Total 98 797 100% 11%

Unconsolidated sales – September and 9 months

According to preliminary unconsolidated figures, JSC Olainfarm sales reached 9.5 million euros in September, which represents an increase by 37% compared to September, 2018. Sale of products improved in Russia (+27%), Latvia (+16%), Belarus (+9%), Ukraine (+95%), Kazakhstan (+736%), Uzbekistan (+542%) and Mongolia (722%). Active pharmaceutical ingredients were sold to clients in Brazil, Egypt and India.

The unconsolidated sales results for the first nine months of 2019 show that JSC Olainfarm sales reached 75 million euros, which represents an increase by 11% compared to the first nine months of 2018. During this reporting period, sales have increased in nine out of the ten major markets of Olainfarm – Russia (+16%), Latvia (+4%), Belarus (+6%), Uzbekistan (+50%), the Netherlands (+189%), Kazakhstan (+1%), Germany (+4%), Tajikistan (+16%) and in Italy (+47%). Revenues declined by 2% in Ukraine.

September 2019, unconsolidated sales Sales, thous. EUR Share in total sales Changes to September 2018
Russia 4 476 47% 27%
Latvia 1 534 16% 13%
Belarus 887 9% 76%
Ukraine 663 7% 95%
Kazakhstan 354 4% 736%
Uzbekistan 182 2% 542%
Brazil 151 2% N/A
Egypt 142 1% N/A
India 133 1% N/A
Mongolia 129 1% 722%
Other 873 9% -22%
Total 9 523 100% 37%

Nine months 2019 unconsolidated sales Sales, thous. EUR Share in total sales Changes to nine months 2018
Russia 26 390 35% 16%
Latvia 12 901 17% 4%
Belarus 9 638 13% 6%
Ukraine 7 856 10% -2%
Uzbekistan 2 427 3% 50%
The Netherlands 1 802 2% 189%
Kazakhstan 1 550 2% 1%
Germany 1 487 2% 4%
Tajikistan 1 215 2% 16%
Italy 1 102 1% 47%
Other 8 554 11% 4%
Total 74 923 100% 11%

Results of subsidiaries – September and the first nine months of 2019

The pharmacy chain SIA Latvijas Aptieka sales reached 2.2 million euros in September 2019, which represents a 11% increase compared to September 2018. 68 pharmacies were operating during this period. SIA Silvanols sales reached 0.6 million euros in September 2019, representing an increase by 4% vs. September 2018. The combined sales of Tonus Elast and Elast Medical in September 2019 were 0.8 million euros, which is by 1% less than this time last year. Olainmed and Diamed Medical Center sales reached 0.27 million euros, while the Belarus subsidiary NPK Biotest reached 0.28 million euros in sales in September that is higher by 43% than in September last year.

During the first nine month period of 2019, SIA Latvijas Aptieka sales amounted to 19.2 million euros, demonstrating an 8% increase in comparison to the same time period last year. Sales of SIA Silvanols reached 4.2 million euros which is 2% less than last year. The combined sales of Tonus Elast and Elast Medical during nine months this year totaled 7.1 million euros which is an increase by 1%. Medical Centers Diamed and Olainmed revenues were 2.3 million euros during the first nine months of this year and the Belarus company NPK Biotest sales were worth 2.3 million euros, improving the result of the last year by 33%.

  September 2019 9 months 2019
Sales markets of Olainfarm 33 45
Sales markets of the Group 38 54
Number of pharmacies 68  
Sales of Latvijas Aptieka, thous. EUR 2 167 19 199
Sales of Medical centers, thous. EUR 264 2 316
Sales of NPK Biotest, thous. EUR 281 2 258
Sales of Tonus Elast and Elast Medical, thous. EUR 833 7 138
Sales of Silvanols, thous. EUR 607 4 179

According to the JSC Olainfarm budget, unconsolidated sales are planned to reach 99 million euros in 2019, while consolidated sales are expected at 133 million euros.  According to these preliminary sales figures, in the first nine months of 2019, 76% of annual target for unconsolidated sales and 74% of annual target for consolidated sales have been reached.

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 45 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company's operations is to produce reliable and effective top -quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 60 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

Additional information:
Jānis Dubrovskis
Investor Relations Advisor of JSC Olainfarm
Phone: +371 29178878

About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

PRF: AS PRFoods’ unaudited preliminary consolidated turnover of the 4th quarter and 12 months of the 2019/2020 financial year12.7.2020 14:14:14 CESTPress release

PRFoods’ unaudited preliminary consolidated turnover in 4th quarter of the fiscal year 2019/2020 amounted to EUR 15.11 million euros, decreased by 29.5% compared to the same period a year ago (4Q 2018/2019: 21.42 million euros). The preliminary turnover of the first 12 months of the financial year was 78.34 million euros (12m 2018/2019: 85.61 million euros). The Q4 decline in sales was 29.5%; including sales increase in retail sector by 7.3%, sales decrease in HoReCa sector by 65.0% and in wholesale sector by 49.6% (partly also influenced by HoReCa sector) compared to the same period previous year; The 12-months sales decrease compared the same period a year ago was 8.5%, mainly affected by lower sales figure in the 4th quarter. During 2019/2020 the product portfolio experienced a change where raw fish and fillets’ segment increased by 4 pp and smoked products declined accordingly. Indrek Kasela, CEO, PRFoods : „Last quarter was defined by the fact that most countries took drastic meas

Volta Finance Limited: Net Asset Value as at 30 June 202010.7.2020 18:25:06 CESTPress release

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES ***** Guernsey, 10 July 2020 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for June. The full report is attached to this release and will be available on Volta’s website shortly ( PERFORMANCE and PORTFOLIO ACTIVITY June delivered another month of strong performance after May and April, helping further to recover the mark-to-market impact of the COVID-19 pandemic. Accounting for the €0.10 per share dividend paid 16th of June, Volta’s NAV* total return performance in June was +6.9%. With the increased confidence around cash flows from underlying assets over the medium term, not only was the Company able to restore the dividend ordinarily payable in April but has further declared a dividend of €0.11 per share payable on 29th July 2020, which is a return to the Company’s original payment timetable. The monthly perfo

Agfa-Gevaert: Publication of a transparency notification – Regulated information10.7.2020 17:40:00 CESTPress release

(Article 14 of the law of May 2, 2007 on the disclosure of significant shareholdings) Mortsel, Belgium – July 10, 2020 - 5.40 p.m. CET According to Agfa-Gevaert NV’s bylaws, the threshold as from which a shareholding needs to be disclosed, has been set at 3%, 5% and a multiple of 5%. In conformity with the Law of May 2, 2007 regarding the disclosure of significant shareholdings in listed companies, Agfa-Gevaert (Euronext: AGFB) discloses the following declaration: On July 3, 2020, Classic Fund Management AG has announced that as per July 1, 2020, its stake in Agfa-Gevaert is less than 3%. Notifications of important shareholdings to be made according to the Law of May 2, 2007 or Agfa-Gevaert NV’s bylaws, should be sent to Contact: Viviane Dictus Director Corporate Communications tel. ++32 (0) 3 444 7124 e-mail: Attachment 20200710 Classic Fund UK

Mandalay Resources Corporation meddelar sina produktions- och försäljningsresultat för andra kvartalet 202010.7.2020 15:17:47 CESTPressemelding

TORONTO, July 10, 2020 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) tillkännagav idag sina produktions- och försäljningsresultat för andra kvartalet 2020. Under andra kvartalet 2020 producerade Mandalay en konsoliderad mängd motsvarande 24 752 säljbara uns guldekvivalent och sålde 24 916 uns guldekvivalent. Mandalays President och Chief Executive Officer, Dominic Duffy förklarade, ”Båda verksamheterna har fortsatt sin starka start på året med förbättrade resultat från första till andra kvartalet vad gäller total mängd sålda uns guldekvivalent. Produktionsresultatet för andra kvartalet var bolagets bästa konsoliderade guldproduktion för ett enskilt kvartal sedan fjärde kvartalet 2017.” Duffy konstaterade vidare, ”Resultaten i Costerfield var fortsatt utmärkta från Youle-ådern, vars anläggning producerade 13 502 uns guldekvivalent. Antimonproduktionen hade ännu ett stabilt kvartal med 933 sålda ton, vilket var bolagets högsta mä

Volta Finance Limited : Director Declaration10.7.2020 15:09:22 CESTPress release

Volta FinanceLimited (VTA/VTAS) Director Resignation Guernsey, 10 July 2020 Volta Finance Limited (the “Company”) announces that Atosa Moini, a non-executive director of the Company and Chair of the Management Engagement Committee, has notified the Company of her intention to step down from her role on the Board and resign as a Director of the Company with effect from 31st July 2020. Ms Moini has been on the Board since 2017 and the Directors would like to express their gratitude to her for her valuable contribution during that period. For further information, please contact: Company Secretary and Administrator BNP Paribas Securities Services S.C.A, Guernsey Branch +44 (0) 1481 750 853

Bergman & Beving AB: The Annual Report for 2019/2020 has been published10.7.2020 15:00:00 CESTPress release

Press release The Annual Report for 2019/2020 has been published Bergman & Beving’s Annual Report for the financial year 1 April 2019–31 March 2020 has been published on the company's website today where it can be downloaded as a PDF version. Stockholm, 10 July 2020 Bergman & Beving AB (publ) For further information, please contact: Peter Schön, CFO, phone no.: +46 70 339 89 99 This information is information that Bergman & Beving AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 3.00pm CET on 10 July 2020. Bergman & Beving owns and refines companies that develop and market strong brands for professional users in industry and construction, mainly in the Nordic region, the Baltic States and Poland. Bergman & Beving aims to enable successful product companies to take the next step and become leading brands in their categories. The Group currently has some 20 brands, about 1,000 employees and revenue of approximate